



**Geneva, Switzerland, and Great Neck, New York** September 22, 2009 – Selexis SA ("Selexis") and Neogenix Oncology, Inc. ("Neogenix") today jointly announced a Research Services Agreement for the rapid development of a high-performance CHO based production cell line expressing an undisclosed Neogenix antibody. The cell line will be developed by Selexis scientists utilizing the industry leading Selexis SURE Cell Line Development™ Platform.

"We are very appreciative to have this opportunity to establish a strong partnership with the world class scientists at Neogenix as the company develops innovative therapies for the management of serious and difficult to treat cancers," said Dr Igor Fisch, CEO and co-founder of Selexis, SA. "By targeting antigens shown only to be associated with tumor cells, Neogenix is in a unique position with regards to treating cancer, making this a very special program to us."

"After careful consideration Neogenix chose Selexis for this important project based on their industry reputation and proven record of performance in being able to quickly generate production cell lines to support high demand antibody programs like ours," said Dr. Andrew Bristol, Vice President of Research and Development of Neogenix.

Neogenix Oncology, Inc. announced last week that the Food and Drug Administration (FDA) has granted permission for the company to begin a Phase I trial with its first therapeutic antibody, NPC-1C under its first IND (Investigational New Drug Application). This first human trial will evaluate the safety of NPC-1C in patients with late stage pancreatic or colorectal cancer. The project being undertaken with Selexis will make an important contribution toward the development and potential commercialization of this and other potential Neogenix products.

*About Selexis:*

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells – Selexis Genetic Elements™. Selexis has further developed platforms, to include: Selexis SUREtech Vectors™, Selexis SUREfection™, Selexis SURE Cell Line Development™ and Selexis INTEGRA-D2M™.

*About Neogenix Oncology, Inc.*

Founded in 2004, Neogenix Oncology, Inc., headquartered in Great Neck, NY, is a research-driven biopharmaceutical company that develops and commercializes innovative diagnostics and therapeutics for the management of solid tumors. Neogenix's pipeline is derived in part from the Hollinshead library of clinically tested vaccines, with the potential to develop products for a wide range of cancers, including colorectal, prostate, lung, ovarian, squamous, and others. The company conducts its research and development work in its laboratories in Great Neck, NY and in Rockville, MD. For more information, please visit the company's website at [www.neogenixoncology.com](http://www.neogenixoncology.com).

More information:

Phone: +41 (0)22 308 93 60

Email: [SURE@selexis.com](mailto:SURE@selexis.com)